LAC24 Antibody

What is LACTB and what role does it play in cellular biology?

LACTB is a protein with a molecular weight of approximately 54 kDa that has been implicated in tumor suppression mechanisms, particularly in epithelial cancers. Research has demonstrated that LACTB functions as a tumor suppressor in ovarian cancer through down-regulation of Slug and induction of differentiation pathways . Understanding LACTB's cellular functions is essential for researchers investigating metabolic regulation and tumorigenesis mechanisms. When designing experiments to study LACTB, researchers should consider its expression patterns across different tissue types and its potential interactions with key signaling pathways involved in cell differentiation.

What are the optimal applications for LACTB antibodies in laboratory research?

LACTB antibodies are primarily optimized for Western Blotting applications at a recommended dilution of 1:1000 . These antibodies show reactivity with human, mouse, rat, and monkey samples, making them versatile for comparative studies across species . For optimal results in immunohistochemistry, researchers should use polyclonal LACTB antibodies (such as catalog number 18195-1-AP) at a 1:200 dilution as demonstrated in tissue microarray studies examining LACTB expression in ovarian cancer tissues . When designing experiments, ensure proper positive and negative controls are included to validate antibody specificity.

What are HLA-A*24:02-restricted epitopes and why are they important in immunological research?

HLA-A24:02 is a human leukocyte antigen allele that is predominant in East Asian populations and plays a critical role in antigen presentation to cytotoxic T lymphocytes (CTLs) . HLA-A24:02-restricted epitopes are specific peptide sequences that bind to this HLA molecule and can be recognized by CTLs, making them valuable targets for vaccine development and immunotherapy approaches. Researchers have identified multiple HLA-A*24:02-restricted epitopes from viral proteins like SARS-CoV-2 nonstructural polyprotein 1a (pp1a) that show conservation across variants, suggesting potential utility in developing broadly effective vaccines .

What is the recommended protocol for analyzing LACTB expression in tumor samples?

For analyzing LACTB expression in tumor samples, researchers should employ a multi-modal approach combining immunohistochemistry and molecular techniques. For tissue microarrays, use LACTB polyclonal antibody at 1:200 dilution and develop a scoring system based on expression intensity compared to normal tissues (e.g., scores 0-3) . For quantitative analysis, extract RNA using standardized kits (e.g., RNeasy Plus Mini kit) followed by RT-PCR with appropriate reference genes for normalization. HPRT has been validated as a suitable reference gene for LACTB expression studies . When comparing expression across different samples, normalize data using the 2^-ΔΔCt method and validate protein expression changes with Western blot using RIPA buffer for protein extraction and appropriate protease/phosphatase inhibitors .

How should researchers design experiments to identify novel HLA-A*24:02-restricted epitopes?

Identification of novel HLA-A24:02-restricted epitopes requires a systematic approach combining computational prediction and experimental validation. Begin with computational algorithms to screen protein sequences for potential binding motifs specific to HLA-A24:02. Then validate candidate epitopes using transgenic mice expressing HLA-A*24:02 and employ peptide-encapsulated liposomes for delivery . The conservation analysis of identified epitopes is crucial, particularly when targeting viral proteins like those from SARS-CoV-2. Researchers should examine large sequence databases to assess epitope conservation across variants, focusing on those that maintain stable amino acid sequences despite mutations in the broader viral genome . This comprehensive approach ensures identification of epitopes with potential therapeutic value.

What methods are most effective for studying LACTB's tumor suppressor functions?

To study LACTB's tumor suppressor functions effectively, researchers should employ a combination of genetic manipulation and functional assays. Begin by establishing stable cell lines with controlled LACTB expression using lentiviral vectors such as FUW-tetON containing human LACTB cDNA . For knockdown studies, use targeted shRNA approaches. Functional assessment should include proliferation assays, using EdU incorporation measured by flow cytometry, and 3D culture methods such as sphere assays to evaluate stemness characteristics . Specifically, seed 5,000 cells in ultra-low attachment plates with appropriate media (DMEM F12 supplemented with B27, EGF, and insulin) and quantify spheres larger than 50 μM after 10 days . For mechanistic studies, analyze key downstream targets like Slug through both protein (Western blot) and mRNA expression levels (qRT-PCR).

How can researchers optimize antibody discovery using the LacO/LacI regulatory system?

The LacO/LacI regulatory system offers a powerful platform for accelerated antibody discovery by controlling immunoglobulin gene diversification. To implement this system, researchers should first engineer cells (such as DT40 cells) by introducing polymerized lactose operator (PolyLacO) upstream of the immunoglobulin λ light chain gene through homologous gene targeting . Optimization requires expression of appropriate regulatory factors fused to LacI to control the rate and outcome of diversification. For selection of high-affinity antibodies, researchers should use a combination of enrichment methods, beginning with antigen-conjugated magnetic beads followed by successive rounds of FACS . When measuring binding affinity improvements, utilize saturation binding kinetics with increasing concentrations of antigen to determine equilibrium affinity (kD). This platform allows for rapid discovery of high-affinity monoclonal antibodies (<10 nM) within 4-8 weeks, with subnanomolar affinity achievable in 8-12 weeks .

What are the critical factors in humanizing chicken-derived antibodies identified through the DTLacO platform?

When humanizing chicken-derived antibodies from the DTLacO platform, researchers must carefully maintain antigen binding affinity while minimizing immunogenicity. The process involves creating appropriate scaffolds for CDR grafting by modifying human framework regions to achieve identity with the Vernier zone residues of the corresponding chicken VH or Vλ region . This approach produces framework scaffolds that are 94-96% identical to human sequences, minimizing potential immunogenicity. Researchers should also consider eliminating the first two N-terminal residues of light chains, as these proximal residues to CDR1 might interfere with antigen binding . The effectiveness of humanization should be validated through comparative binding assays, comparing the apparent binding affinities of the original and humanized antibodies. This methodology has demonstrated successful humanization without loss of affinity for antibodies targeting complex antigens like FN14 and FZD10 .

What are the common challenges in detecting LACTB expression in clinical samples and how can they be addressed?

Detection of LACTB expression in clinical samples presents several challenges including tissue heterogeneity, variable fixation conditions, and potential cross-reactivity. To address these issues, researchers should: (1) Optimize antibody concentration through titration experiments using positive and negative control tissues; (2) Implement proper antigen retrieval methods specific to the fixation protocol used; (3) Develop a standardized scoring system based on expression intensity compared to normal tissues (scores 0-3); and (4) Validate immunohistochemical findings with orthogonal methods such as qRT-PCR when possible . For tissue microarray analysis, ensure adequate biological replication (the referenced study examined 331 patient samples) . When interpreting results, consider compartment-specific expression patterns (luminal versus basal) and compare expression to matched normal tissues rather than using absolute values.

How should researchers analyze and interpret conservation data for HLA-A*24:02-restricted epitopes?

When analyzing conservation data for HLA-A24:02-restricted epitopes, researchers should employ a systematic approach examining mutation frequencies across large viral sequence databases. The analysis should focus on amino acid substitutions specifically within the epitope sequence rather than the entire protein. For example, when studying SARS-CoV-2 epitopes from pp1a, researchers identified 7 out of 22 epitopes that maintained remarkable conservation despite numerous mutations in the broader Sequence Read Archive database . Interpretation should consider: (1) The functional importance of conserved regions, as essential viral proteins tend to tolerate fewer mutations; (2) The potential impact of mutations on HLA binding affinity using in silico prediction algorithms; and (3) The geographic distribution of HLA-A24:02 in target populations, particularly its high prevalence in East Asian populations . This comprehensive analysis helps identify epitopes with potential universal efficacy against variant strains.

What statistical approaches are recommended for quantifying LACTB expression differences in tumor versus normal tissues?

For quantifying LACTB expression differences between tumor and normal tissues, researchers should implement robust statistical methodologies that account for data variability and potential confounding factors. When analyzing qRT-PCR data, first normalize gene expression using validated reference genes (HPRT has been demonstrated as suitable for LACTB studies) . Calculate relative expression using the 2^-ΔΔCt method with appropriate error propagation. For immunohistochemical studies using tissue microarrays, develop a categorical scoring system (0-3) based on staining intensity and distribution, then apply non-parametric tests (e.g., Mann-Whitney U test) to compare expression scores between tumor and normal tissues . For larger datasets, consider multivariate analysis to adjust for clinicopathological variables that might influence LACTB expression. When reporting results, include both statistical significance (p-values) and effect sizes to provide a complete picture of LACTB expression differences.

How can researchers effectively measure the functional impact of LACTB on cancer cell stemness and differentiation?

To effectively measure LACTB's impact on cancer cell stemness and differentiation, researchers should implement a multi-parametric approach combining functional assays with molecular profiling. Start with sphere formation assays in ultra-low attachment plates, counting spheres over 50 μM in diameter after 10 days of culture in stem cell media (DMEM F12 supplemented with B27, EGF, and insulin) . Complement this with flow cytometry analysis of established stem cell markers appropriate for the cancer type being studied. At the molecular level, quantify expression changes in stemness-associated genes and differentiation markers using qRT-PCR. Key genes to evaluate include SLUG, CD44, TGM2, WNT5A, INHBA, LAMA3, GLIPR1, and SERPINE2 . For mechanistic studies of LACTB's tumor suppressor function, perform rescue experiments by co-expressing LACTB with its downstream targets like SLUG using appropriate lentiviral vectors (FUW-tetON for LACTB expression and FUW-LPT2 for SLUG) . This comprehensive approach provides both phenotypic and mechanistic insights into LACTB's role in regulating the differentiation state of cancer cells.

What are the potential applications of HLA-A*24:02-restricted epitopes in next-generation vaccine development?

HLA-A24:02-restricted epitopes show significant promise for next-generation vaccine development, particularly for populations with high HLA-A24:02 prevalence such as East Asians. These epitopes can complement traditional antibody-inducing approaches by engaging cellular immunity through cytotoxic T lymphocytes (CTLs) . For viral pathogens like SARS-CoV-2, researchers have identified conserved epitopes from nonstructural proteins such as pp1a that remain stable across variants, potentially offering broader protection than current spike-focused vaccines . Future vaccine development should consider incorporating these conserved epitopes alongside neutralizing antibody targets to create dual-action vaccines that remain effective against emerging variants. The methodology for identifying such epitopes—combining computational prediction, HLA-A*24:02 transgenic mice, and peptide-encapsulated liposomes—provides a template for developing similar approaches against other pathogens .

How might new antibody engineering technologies enhance the DTLacO platform for monoclonal antibody discovery?

The DTLacO platform offers rapid ex vivo discovery of high-affinity monoclonal antibodies, but integration with emerging antibody engineering technologies could further enhance its capabilities. Potential advancements include: (1) Incorporation of CRISPR-Cas9 gene editing for precise manipulation of immunoglobulin genes to control mutation patterns; (2) Implementation of deep learning algorithms to predict optimal CDR sequences based on antigen structure; and (3) Development of high-throughput single-cell sequencing methods to rapidly identify promising antibody candidates from diversified populations . A significant advantage of the DTLacO platform is that it produces intact antibodies rather than single-chain fragments, facilitating immediate functional testing . Future developments could focus on engineering the platform to specifically target challenging antigens such as G protein-coupled receptors and ion channels, which are traditionally difficult for antibody development but represent important therapeutic targets.

What methodological advances might improve studies of LACTB's role in tumor microenvironment interactions?

Advanced methodologies for studying LACTB's role in tumor microenvironment interactions should focus on spatial analysis and dynamic monitoring of protein function. Emerging approaches might include: (1) Spatial transcriptomics and proteomics to map LACTB expression and its downstream effects within the complex tumor architecture; (2) Development of biosensors to monitor LACTB activity in real-time within living cells and tissues; and (3) Organoid co-culture systems that incorporate stromal and immune components to better recapitulate tumor-microenvironment interactions . Additionally, conditional expression systems that allow temporal control of LACTB activity could help distinguish between direct and indirect effects on tumor progression. Since LACTB has been shown to function as a tumor suppressor through mechanisms including Slug down-regulation , future studies should also explore how LACTB influences communication between cancer cells and surrounding stromal and immune cells, potentially through altered secretion of paracrine factors or changes in cell surface protein expression.